Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | BLVRB | P30043 | 1/20 | 0.48 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338008 | 0.81 | XDH (0.49) | XDH | |
| SCHEMBL31421752 | 0.77 | XDH (0.55) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL31573 | 0.76 | XDH (0.69) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL4340831 | 0.75 | XDH (0.62) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL4335034 | 0.73 | XDH (0.54) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL12133604 | 0.70 | XDH (0.73) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL28324542 | 0.69 | XDH (0.59) | XDHSLC22A12 | |
| SCHEMBL22113143 | 0.69 | XDH (0.68) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL28280399 | 0.68 | XDH (0.74) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL5827419 | 0.68 | S1PR1 (0.57) | XDHABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612108-B2 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1783124-A1 | 2-PHENYLTHIOPHENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | XDH, UACA, NUDT1 | XDH 1/4885ABCC4 271/4885ABCB11 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.